Is modulation of oxidative stress an answer? the state of the art of redox therapeutic actions in neurodegenerative diseases

Oxidative Medicine and Cellular Longevity

Volumn 2016, Issue , 2016, Pages

  Chiurchiù, Valerio ^a,b   Orlacchio, Antonio ^b,c   Maccarrone, Mauro ^a,b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

METAL IONS; METALS; MODULATION; OXIDATIVE STRESS;

ALZHEIMER'S DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CENTRAL NERVOUS SYSTEMS; DEPOSITION OF METALS; MULTIPLE SCLEROSIS; PARKINSON'S DISEASE; REACTIVE OXYGEN AND NITROGEN SPECIES; THERAPEUTIC STRATEGY;

NEURODEGENERATIVE DISEASES;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; DEGENERATIVE DISEASE; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; AGING; BLOOD BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM; CHEMISTRY; INFLAMMATION; METABOLISM; OXIDATION REDUCTION REACTION; OXYGEN CONSUMPTION;

ION; METAL; OXYGEN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE;

AGING; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BLOOD-BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM; HUMANS; INFLAMMATION; IONS; METALS; NEURODEGENERATIVE DISEASES; OXIDATION-REDUCTION; OXIDATIVE STRESS; OXYGEN; OXYGEN CONSUMPTION; PARKINSON DISEASE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; SPASTIC PARAPLEGIA, HEREDITARY;

EID: 84957073278     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2016/7909380     Document Type: Review

References (103)

1. B. Halliwell and J. M. Gutteridge, Free radicals in Biology and Medicine, Oxford University Press, Oxford, UK, 3rd edition, 1999.
2. V. Chiurchiu and M. MacCarrone, "Chronic inflammatory disorders and their redox control: from molecular mechanisms to therapeutic opportunities, "Antioxidants and Redox Signaling, vol. 15, no. 9, pp. 2605-2641, 2011.
3. W. Droge, "Free radicals in the physiological control of cell function, " Physiological Reviews, vol. 82, no. 1, pp. 47-95, 2002.
4. J. Aikens and T. A. Dix, "Perhydroxyl radical (HOO) initiated lipid peroxidation: the role of fatty acid hydroperoxides, " The Journal of Biological Chemistry, vol. 266, pp. 15091-15098, 1991.
5. D. Trachootham, W. Lu, M. A. Ogasawara, N. R.-D. Valle, and P. Huang, "Redox regulation of cell survival, " Antioxidants and Redox Signaling, vol. 10, no. 8, pp. 1343-1374, 2008.
6. S. Raha and B. H. Robinson, "Mitochondria, oxygen free radicals, disease and ageing, " Trends in Biochemical Sciences, vol. 25, no. 10, pp. 502-508, 2000.
7. L. M. Henderson and J. B. Chappell, "NADPH oxidase of neutrophils, " Biochimica et Biophysica Acta: Bioenergetics, vol. 1273, no. 2, pp. 87-107, 1996.
8. J. S. Stamler, D. J. Singel, and J. Loscalzo, "Biochemistry of nitric oxide and its redox-activated forms, " Science, vol. 258, no. 5090, pp. 1898-1902, 1992.
9. J. Leiper and M. Nandi, "The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis, " Nature Reviews Drug Discovery, vol. 10, no. 4, pp. 277-291, 2011.
10. L. L. Moroz, S. W. Norby, L. Cruz, J. V. Sweedler, R. Gillette, and R. B. Clarkson, "Non-enzymatic production of nitric oxide (NO) from NO synthase inhibitors, " Biochemical and Biophysical Research Communications, vol. 253, no. 3, pp. 571-576, 1998.
11. A. Zanotto-Filho, R. Schroder, and J. C. F. Moreira, "Xanthine oxidase-dependent ROS production mediates vitamin A prooxidant effects in cultured sertoli cells, " Free Radical Research, vol. 42, no. 6, pp. 593-601, 2008.
12. Y. Yang, A. V. Bazhin, J. Werner, and S. Karakhanova, "Reactive oxygen species in the immune system, " International Reviews of Immunology, vol. 32, no. 3, pp. 249-270, 2013.
13. J. Lugrin, N. Rosenblatt-Velin, R. Parapanov, and L. Liaudet, "The role of oxidative stress during inflammatory processes, " Biological Chemistry, vol. 395, no. 2, pp. 203-230, 2014.
14. M. Kobayashi and M. Yamamoto, "Molecularmechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation, " Antioxidants and Redox Signaling, vol. 7, no. 3-4, pp. 385-394, 2005.
15. R. Noubade, K. Wong, N. Ota et al., "NRROS negatively regulates reactive oxygen species during host defence and autoimmunity, " Nature, vol. 509, no. 7499, pp. 235-239, 2014.
16. V. Chiurchiu, "Novel targets in multiple sclerosis: to oxidative stress and beyond, " Current Topics in Medicinal Chemistry, vol. 14, no. 22, pp. 2590-2599, 2014.
17. D. Leppert, E. Waubant, R. Galardy, N. W. Bunnett, and S. L. Hauser, "T cell gelatinases mediate basement membrane transmigration in vitro, " Journal of Immunology, vol. 154, no. 9, pp. 4379-4389, 1995.
18. H. Langemann, A. Kabiersch, and J. Newcombe, "Measurement of low-molecular weight antioxidants, uric acid, tyrosine and tryptophan in plaques and white matter from patients with multiple sclerosis, " European Neurology, vol. 32, no. 5, pp. 248-252, 1992.
19. C. Lehner, R. Gehwolf, H. Tempfer et al., "Oxidative stress and blood-brain barrier dysfunction under particular consideration of matrix metalloproteinases, " Antioxidants and Redox Signaling, vol. 15, no. 5, pp. 1305-1323, 2011.
20. A. Robert, Y. Liu, M. Nguyen, and B. Meunier, "Regulation of copper and iron homeostasis by metal chelators: a possible chemotherapy for Alzheimers disease, " Accounts of Chemical Research, vol. 48, no. 5, pp. 1332-1339, 2015.
21. J. Jankovic, "Parkinsons disease: clinical features and diagnosis, " Journal of Neurology, Neurosurgery and Psychiatry, vol. 79, no. 4, pp. 368-376, 2008.
22. C. W. Shults, D. Oakes, K. Kieburtz et al., "Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline, " Archives of Neurology, vol. 59, no. 10, pp. 1541-1550, 2002.
23. A. Storch, W. H. Jost, P. Vieregge et al., "Randomized, doubleblind, placebo-controlled trial on symptomatic effects of coenzyme Q10 in Parkinson disease, " Archives of Neurology, vol. 64, no. 7, pp. 938-944, 2007.
24. L. Shinto, G. Marracci, S. Baldauf-Wagner et al., "Omega-3 fatty acid supplementation decreases matrix metalloproteinase-9 production in relapsing-remitting multiple sclerosis, , " Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 80, no. 2-3, pp. 131-136, 2009.
25. V. Ramirez-Ramirez, M. A. Macias-Islas, G. G. Ortiz et al., "Efficacy of fish oil on serum of TNFα, IL-1β, and IL-6 oxidative stress markers inmultiple sclerosis treated with interferon beta-1b, " OxidativeMedicine and Cellular Longevity, vol. 2013, Article ID 709493, 8 pages, 2013.
26. Z. Li, P. Wang, Z. Yu et al., "The effect of creatine and coenzyme q10 combination therapy on mild cognitive impairment in Parkinsons disease, " European Neurology, vol. 73, no. 3-4, pp. 205-211, 2015.
27. L. K. Mischley, J. B. Leverenz, R. C. Lau et al., "A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinsons disease, " Movement Disorders, vol. 30, no. 12, pp. 1696-1701, 2015.
28. J. K. Andersen, D. Kaur, F. Yantiri et al., "Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinsons disease, " Neuron, vol. 37, no. 6, pp. 899-909, 2003.
29. S. R. Bareggi and U. Cornelli, "Clioquinol: review of its mechanisms of action and clinical uses in neurodegenerative disorders, " CNS Neuroscience and Therapeutics, vol. 18, no. 1, pp. 41-46, 2012.
30. J. Blesa, I. Trigo-Damas, A. Quiroga-Varela, and V. R. Jackson- Lewis, "Oxidative stress and Parkinsons disease, " Frontiers in Neuroanatomy, vol. 9, article 91, 2015.
31. R. Pamphlett, "Uptake of environmental toxicants by the locus ceruleus: a potential trigger for neurodegenerative, demyelinating and psychiatric disorders, " Medical Hypotheses, vol. 82, no. 1, pp. 97-104, 2014.
32. S. B. Berman and T. G. Hastings, "Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinsons disease, " Journal of Neurochemistry, vol. 73, no. 3, pp. 1127-1137, 1999.
33. B. Swinnen and W. Robberecht, "The phenotypic variability of amyotrophic lateral sclerosis, " Nature Reviews Neurology, vol. 10, no. 11, pp. 661-670, 2014.
34. G. D. Ghadge, J. P. Lee, V. P. Bindokas et al., "Mutant superoxide dismutase-1-linked familial amyotrophic lateral sclerosis: molecular mechanisms of neuronal death and protection, " The Journal of Neuroscience, vol. 17, no. 22, pp. 8756-8766, 1997.
35. S. Ruggieri, C. Tortorella, and C. Gasperini, "Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis, " Therapeutics and Clinical Risk Management, vol. 10, pp. 229-239, 2014.
36. R. J. Fox, M. Kita, S. L. Cohan, et al., "BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety, " Current Medical Research and Opinion, vol. 30, no. 2, pp. 251-262, 2014.
37. J. H. Noseworthy, C. Lucchinetti, M. Rodriguez, and B. G. Weinshenker, "Multiple sclerosis, " The New England Journal of Medicine, vol. 343, no. 13, pp. 938-952, 2000.
38. W. I. McDonald, A. Compston, G. Edan et al., "Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis, " Annals of Neurology, vol. 50, no. 1, pp. 121-127, 2001.
39. H. W. Querfurth and F. M. LaFerla, "Alzheimers disease, " The New England Journal of Medicine, vol. 362, no. 4, pp. 329-344, 2010.
40. Y. Huang and L. Mucke, "Alzheimer mechanisms and therapeutic strategies, " Cell, vol. 148, no. 6, pp. 1204-1222, 2012.
41. F. M. LaFerla, K. N. Green, and S. Oddo, "Intracellular amyloid- β in Alzheimers disease, " Nature Reviews Neuroscience, vol. 8, no. 7, pp. 499-509, 2007.
42. D. Di Bona, G. Scapagnini, G. Candore et al., "Immuneinflammatory responses and oxidative stress in Alzheimers disease: therapeutic implications, " Current Pharmaceutical Design, vol. 16, no. 6, pp. 684-691, 2010.
43. X. Zhu, A. K. Raina, H.-G. Lee, G. Casadesus, M. A. Smith, and G. Perry, "Oxidative stress signalling in Alzheimers disease, " Brain Research, vol. 1000, no. 1-2, pp. 32-39, 2004.
44. R. von Bernhardi and J. Eugenin, "Alzheimers disease: redox dysregulation as a common denominator for diverse pathogenic mechanisms, " Antioxidants and Redox Signaling, vol. 16, no. 9, pp. 974-1031, 2012.
45. D. A. Butterfield, A. Gnjec, H. F. Poon et al., "Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimers disease: an initial assessment, " Journal of Alzheimers Disease, vol. 10, no. 4, pp. 391-397, 2006.
46. H. P. Lee, X. Zhu, G. Casadesus et al., "Antioxidant approaches for the treatment of Alzheimers disease, " Expert Review of Neurotherapeutics, vol. 10, no. 7, pp. 1201-1208, 2010.
47. B. Frank and S. Gupta, "A review of antioxidants and Alzheimers disease, " Annals of Clinical Psychiatry, vol. 17, no. 4, pp. 269-286, 2005.
48. M. E. S. Ferreira, A. S. de Vasconcelos, T. da CostaVilhena et al., "Oxidative stress in Alzheimers disease: should we keep trying antioxidant therapies?" Cellular and Molecular Neurobiology, vol. 3, no. 5, pp. 595-614, 2015.
49. A. I. Bush and R. E. Tanzi, "Therapeutics for Alzheimers disease based on the metal hypothesis, " Neurotherapeutics, vol. 5, no. 3, pp. 421-432, 2008.
50. E. L. Sampson, L. Jenagaratnam, and R. McShane, "Metal protein attenuating compounds for the treatment of Alzheimers dementia, " The Cochrane Database of Systematic Reviews, vol. 21, no. 2, Article ID CD005380, 2014.
51. F. Gu, V. Chauhan, and A. Chauhan, "Glutathione redox imbalance in brain disorders, " Current Opinion in Clinical Nutrition and Metabolic Care, vol. 18, no. 1, pp. 89-95, 2015.
52. E. Carboni and P. Lingor, "Insights on the interaction of alphasynuclein and metals in the pathophysiology of Parkinsons disease, " Metallomics, vol. 7, no. 3, pp. 395-404, 2015.
53. J. L. George, S. Mok, D. Moses et al., "Targeting the progression of Parkinsons disease, " Current Neuropharmacology, vol. 7, no. 1, pp. 9-36, 2009.
54. J. J. Sutachan, Z. Casas, S. L. Albarracin et al., "Cellular and molecular mechanisms of antioxidants in Parkinsons disease, " Nutritional Neuroscience, vol. 15, no. 3, pp. 120-126, 2012.
55. S. E. Seidl, J. A. Santiago, H. Bilyk, and J. A. Potashkin, "The emerging role of nutrition in Parkinsons disease, " Frontiers in Aging Neuroscience, vol. 6, article 36, Article IDArticle 36, 2014.
56. E. Miller, A. Morel, L. Saso, and J. Saluk, "Melatonin redox activity. Its potential clinical applications in neurodegenerative disorders, " Current Topics inMedicinal Chemistry, vol. 15, no. 2, pp. 163-169, 2015.
57. L. Yang, N. Y. Calingasan, E. J. Wille et al., "Combination therapy with Coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinsons and Huntingtons Diseases, " Journal of Neurochemistry, vol. 109, no. 5, pp. 1427-1439, 2009.
58. L. I. Bruijn, M. K. Houseweart, S. Kato et al., "Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1, " Science, vol. 281, no. 5384, pp. 1851-1854, 1998.
59. J. R. McLean, G. A. Smith, E. M. Rocha et al., "ALS-associated peripherin spliced transcripts form distinct protein inclusions that are neuroprotective against oxidative stress, " Experimental Neurology, vol. 261, pp. 217-229, 2014.
60. B. J. Carter, P. Anklesaria, S. Choi, and J. F. Engelhardt, "Redox modifier genes and pathways in amyotrophic lateral sclerosis, " Antioxidants and Redox Signaling, vol. 11, no. 7, pp. 1569-1586, 2009.
61. M. M. Harraz, J. J. Marden, W. Zhou et al., "SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model, " Journal of Clinical Investigation, vol. 118, no. 2, pp. 659-670, 2008.
62. E. D. Hall, P. K. Andrus, J. A. Oostveen, T. J. Fleck, and M. E. Gurney, "Relationship of oxygen radical-induced lipid peroxidative damage to disease onset and progression in a transgenic model of familial ALS, " Journal ofNeuroscience Research, vol. 53, no. 1, pp. 66-77, 1998.
63. P. I. Oteiza, O. D. Uchitel, F. Carrasquedo, A. L. Duborovski, J. C. Roma, and C. G. Fraga, "Evaluation of antioxidants, protein, and lipid oxidation products in blood from sporadic amyotrophic lateral sclerosis patients, " Neurochemical Research, vol. 22, no. 4, pp. 535-539, 1997.
64. R. G. Miller, J. D. Mitchell, M. Lyon, and D. H. Moore, "Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND), " Amyotrophic Lateral Sclerosi and Other Motor Neuron Disorders, vol. 4, no. 3, pp. 191-206, 2003.
65. A. Vyth, J. G. Timmer, P. M. M. Bossuyt, E. S. Louwerse, and J. M. B. Vianney De Jong, "Survival in patients with amyotrophic lateral sclerosis, treated with an array of antioxidants, " Journal of the Neurological Sciences, vol. 139, supplement, pp. 99-103, 1996.
66. J. P. Crow, N. Y. Calingasan, J. Chen, J. L. Hill, and M. F. Beal, "Manganese porphyrin given at symptom onset markedly extends survival of ALS mice, " Annals of Neurology, vol. 58, no. 2, pp. 258-265, 2005.
67. V. K. Gribkoff and M. E. Bozik, "KNS-760704 (6R)-4, 5, 6, 7- tetrahydro-N6-propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate for the treatment of amyotrophic lateral sclerosis, " CNS Neuroscience and Therapeutics, vol. 14, no. 3, pp. 215-226, 2008.
68. B. Broux, P. Stinissen, and N. Hellings, "Which immune cells matter?The immunopathogenesis ofmultiple sclerosis, " Critical Reviews in Immunology, vol. 33, no. 4, pp. 283-306, 2013.
69. R. Gandhi, A. Laroni, and H. L. Weiner, "Role of the innate immune system in the pathogenesis of multiple sclerosis, " Journal of Neuroimmunology, vol. 221, no. 1-2, pp. 7-14, 2010.
70. B. D. Trapp and K.-A. Nave, "Multiple sclerosis: an immune or neurodegenerative disorder?" Annual Review of Neuroscience, vol. 31, pp. 247-269, 2008.
71. H. Lassmann, J. van Horssen, and D. Mahad, "Progressive multiple sclerosis: pathology and pathogenesis, " Nature Reviews Neurology, vol. 8, no. 11, pp. 647-656, 2012.
72. L. Bo, T. M. Dawson, S. Wesselingh et al., "Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains, " Annals of Neurology, vol. 36, no. 5, pp. 778-786, 1994.
73. P. G. Winyard and D. R. Blake, "Antioxidants, redox-regulated transcription factors, and inflammation, " Advances in Pharmacology, vol. 38, pp. 403-421, 1996.
74. D. Leppert, E. Waubant, R. Galardy, N. W. Bunnett, and S. L. Hauser, "T cell gelatinases madiate basement membrane transmigration in vitro, " Journal of Immunology, vol. 154, no. 9, pp. 4379-4389, 1995.
75. E. Karg, P. Klivenyi, I. Nemeth, K. Bencsik, S. Pinter, and L. Vecsei, "Nonenzymatic antioxidants of blood in multiple sclerosis, " Journal of Neurology, vol. 246, no. 7, pp. 533-539, 1999.
76. O. Vladimirova, J. O'Connor, A. Cahill, H. Alder, C. Butunoi, and B. Kalman, "Oxidative damage to DNA in plaques of MS brains, " Multiple Sclerosis, vol. 4, no. 5, pp. 413-418, 1998.
77. C. Syburra and S. Passi, "Oxidative stress in patients withmultiple sclerosis, " Ukrainskii Biokhimicheskii Zhurnal, vol. 71, no. 3, pp. 112-115, 1999.
78. M. Maccarrone, G. Melino, and A. Finazzi-Agro, "Lipoxygenases and their involvement in programmed cell death, " Cell Death and Differentiation, vol. 8, no. 8, pp. 776-784, 2001.
79. R. L. T. Cooper, "Multiple sclerosis: an immune legacy?" Medical Hypotheses, vol. 49, no. 4, pp. 307-311, 1997.
80. D. Lehmann, D. Karussis, R. Misrachi-Koll, E. Shezen, H. Ovadia, and O. Abramsky, "Oral administration of the oxidant- scavenger N-acetyl-l-cysteine inhibits acute experimental autoimmune encephalomyelitis, " Journal of Neuroimmunology, vol. 50, no. 1, pp. 35-42, 1994.
81. B. Malfroy, S. R. Doctrow, P. L. Orr, G. Tocco, E. V. Fedoseyeva, and G. Benichou, "Prevention and suppression of autoimmune encephalomyelitis by EUK-8, a synthetic catalytic scavenger of oxygen-reactivemetabolites, " Cellular Immunology, vol. 177, no. 1, pp. 62-68, 1997.
82. D. C. Hooper, O. Bagasra, J. C. Marini et al., "Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment ofmultiple sclerosis, " Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 6, pp. 2528-2533, 1997.
83. G. von Geldern and E. M. Mowry, "The influence of nutritional factors on the prognosis of multiple sclerosis, " Nature Reviews Neurology, vol. 8, no. 12, pp. 678-689, 2012.
84. J. Lovera, B. Bagert, K. Smoot et al., "Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial, "Multiple Sclerosis, vol. 13, no. 3, pp. 376-385, 2007.
85. Q. Wang, S. Chuikov, S. Taitano et al., "Dimethyl fumarate protects neural stem/progenitor cells and neurons from oxidative damage through Nrf2-ERK1/2 MAPK pathway, " International Journal of Molecular Sciences, vol. 16, no. 6, pp. 13885-13907, 2015.
86. P. Kawalec, A. Mikrut, N. Wisniewska, and A. Pilc, "The effectiveness of dimethyl fumarate monotherapy in the treatment of relapsing-remitting multiple sclerosis: a systematic review and meta-analysis, " Current Neuropharmacology, vol. 12, no. 3, pp. 256-268, 2014.
87. R. J. Fox, D. H. Miller, J. T. Phillips et al., "Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis, " The New England Journal of Medicine, vol. 367, no. 12, pp. 1087-1097, 2012.
88. R. Gold, L. Kappos, D. L. Arnold et al., "Placebo-controlled phase 3 study of oral BG-12 for relapsingmultiple sclerosis, " The New England Journal ofMedicine, vol. 367, no. 12, pp. 1098-1107, 2012.
89. J. T. Phillips and R. J. Fox, "BG-12 inmultiple sclerosis, " Seminars in Neurology, vol. 33, no. 1, pp. 56-65, 2013.
90. J. K. Fink, "Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms, " Acta Neuropathologica, vol. 126, no. 3, pp. 307-328, 2013.
91. C. Blackstone, "Cellular pathways of hereditary spastic paraplegia, " Annual Review of Neuroscience, vol. 35, pp. 25-47, 2012.
92. Y. Wakana, S. Koyama, K.-I. Nakajima et al., "Reticulon 3 is involved in membrane trafficking between the endoplasmic reticulum and Golgi, " Biochemical and Biophysical Research Communications, vol. 334, no. 4, pp. 1198-1205, 2005.
93. G. Orso, D. Pendin, S. Liu et al., "Homotypic fusion of ERmembranes requires the dynamin-like GTPase atlastin, " Nature, vol. 460, no. 7258, pp. 978-983, 2009.
94. T. Lo Giudice, F. Lombardi, F. M. Santorelli, T. Kawarai, and A. Orlacchio, "Hereditary spastic paraplegia: clinical-genetic characteristics and evolving molecular mechanisms, " Experimental Neurology, vol. 261, pp. 518-539, 2014.
95. K. Gucuyener, F. G. Pinarli, D. Erbas, A. Hasanoglu, A. Serdaroglu, and H. Topaloglu, "Is oxidative damage in operation in patients with hereditary spastic paraparesis?" Brain and Development, vol. 32, no. 2, pp. 130-136, 2010.
96. G. Casari, M. De Fusco, S. Ciarmatori et al., "Spastic paraplegia andOXPHOS impairment caused bymutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease, " Cell, vol. 93, no. 6, pp. 973-983, 1998.
97. S. Patel and M. Latterich, "The AAA team: related ATPases with diverse functions, " Trends in Cell Biology, vol. 8, no. 2, pp. 65-71, 1998.
98. C. J. McDermott, R. W. Taylor, C. Hayes et al., "Investigation of mitochondrial function in hereditary spastic paraparesis, " NeuroReport, vol. 14, no. 3, pp. 485-488, 2003.
99. F. Ferreirinha, A. Quattrini, M. Pirozzi et al., "Axonal degeneration in paraplegin-deficient mice is associated with abnormal mitochondria and impairment of axonal transport, " The Journal of Clinical Investigation, vol. 113, no. 2, pp. 231-242, 2004.
100. L. Atorino, L. Silvestri, M. Koppen et al., "Loss of m-AAA protease in mitochondria causes complex I deficiency and increased sensitivity to oxidative stress in hereditary spastic paraplegia, "The Journal of Cell Biology, vol. 163, no. 4, pp. 777-787, 2003.
101. A. Milano, N. M. Gesualdi, R. Teperino, F. Esposito, S. Cocozza, and P. Ungaro, "Oxidative DNA damage and activation of c- Jun N-terminal kinase pathway in fibroblasts from patients with hereditary spastic paraplegia, " Cellular and Molecular Neurobiology, vol. 25, no. 8, pp. 1245-1254, 2005.
102. J. Hansen, T. J. Corydon, J. Palmfeldt et al., "Decreased expression of the mitochondrial matrix proteases Lon and ClpP in cells froma patient with hereditary spastic paraplegia (SPG13), " Neuroscience, vol. 153, no. 2, pp. 474-482, 2008.
103. C. Tesson, M. Nawara, M. A. M. Salih et al., "Alteration of fatty-acid-metabolizing enzymes affects mitochondrial form and function in hereditary spastic paraplegia, "American Journal of Human Genetics, vol. 91, no. 6, pp. 1051-1064, 2012.